KB-1189

Monalizumab

52670

Home » Monalizumab

Background of Monalizumab

CD94/NKG2A heterodimer is a type II transmembrane receptor that belongs to the C-type lectin family containing a single intracellular ITIM domain that recognizes HLA-E, a nonclassical HLA-I molecule. NKG2A participates in NK cell-mediated self-tolerance upon binding to HLA-E, which in turn has been related to tumor evasion in a wide variety of solid tumors and hematological malignancies, such as MM . Monalizumab is a humanized IgG4 antibody that abrogates NKG2A inhibitory function by impeding its interaction with HLA-E. This mAb has already shown promising results in head and neck squamous cell carcinoma (in combination with cetuximab) and gynecological cancers in phase II clinical trials.

Specifications

Catalog Number	KB-1189
Antibody Name	Monalizumab
Isotype	Human-IgG4-S228P, kappa
FC Muations	S228P
Target	NKG2A
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, Andre P, et al. NKG2A blockade potentiates CD8 T cell immunity induced by Cancer vaccines. Cell. 2018;175(7):1744–55 e1715.
Andre P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Blery M, Bonnafous C, Gauthier L, Morel A, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175(7):1731–43 e1713.
Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795–9.